Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Condition: Hematologic Neoplasms Interventions: Drug: Mycophenolate Mofetil; Procedure: Allogeneic HSCT; Drug: Fludarabine; Drug: Sirolimus; Drug: Filgrastim; Drug: Cyclophosphamide; Drug: Mesna; Procedure: Total Body Irradiation (TBI) Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bone Marrow Transplant | Cancer & Oncology | Filgrastim | Hematology | Neulasta | Neupogen | Research | Study | Transplants